Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Gains from Sales and Divestitures (2019 - 2022)

P3 Health Partners' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $5.0 million for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $5.0 million; the TTM value through Dec 2022 reached $5.0 million, changed N/A, while the annual FY2022 figure was $5.0 million, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $5.0 million in Q4 2022 per PIIIW's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $5.0 million in Q4 2022 to a low of $443750.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 4 years is $2.5 million, with a median of $660417.0 recorded in 2021.
  • The largest YoY upside for Gains from Sales and Divestitures was 29.93% in 2020 against a maximum downside of 29.93% in 2020.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $633333.0 in 2019, then fell by 29.93% to $443750.0 in 2020, then skyrocketed by 48.83% to $660417.0 in 2021, then surged by 662.85% to $5.0 million in 2022.
  • Per Business Quant, the three most recent readings for PIIIW's Gains from Sales and Divestitures are $5.0 million (Q4 2022), $5.0 million (Q3 2022), and $4.9 million (Q2 2022).